Profile data is unavailable for this security.
About the company
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
- Revenue in USD (TTM)776.62m
- Net income in USD-384.77m
- Incorporated1991
- Employees927.00
- LocationIonis Pharmaceuticals Inc2855 Gazelle CourtCARLSBAD 92010United StatesUSA
- Phone+1 (760) 931-9200
- Fax+1 (302) 655-5049
- Websitehttps://www.ionispharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 4.98bn | 702.00 | -- | 18.67 | -- | 9.51 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.07bn | 550.00 | -- | -- | -- | 23.22 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 5.14bn | 376.00 | -- | 5.87 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Nuvalent Inc | 0.00 | -145.51m | 5.27bn | 106.00 | -- | 7.80 | -- | -- | -2.41 | -2.41 | 0.00 | 10.47 | 0.00 | -- | -- | 0.00 | -24.88 | -- | -26.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.32bn | 10.00k | 5.07 | 110.17 | 4.12 | 0.8375 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Summit Therapeutics Inc | 0.00 | -116.03m | 5.71bn | 105.00 | -- | 129.09 | -- | -- | -0.1657 | -0.1657 | 0.00 | 0.063 | 0.00 | -- | -- | 0.00 | -53.76 | -77.32 | -59.38 | -86.35 | -- | -- | -- | -20,989.46 | -- | -118.81 | 0.6934 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.82bn | 927.00 | -- | 19.61 | -- | 7.49 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 5.99bn | 423.00 | -- | -- | -- | 1,596.52 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 6.07bn | 28.00 | -- | 6.49 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Exelixis Inc | 1.85bn | 205.05m | 6.46bn | 1.31k | 34.30 | 3.08 | 28.05 | 3.50 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.54bn | 645.00 | -- | 21.04 | -- | 23.17 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 6.55bn | 373.00 | 21.28 | 36.80 | 16.33 | 7.59 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.62bn | 411.00 | -- | 3.84 | -- | 1,450.77 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.70bn | 2.80k | 21.93 | 1.81 | 6.85 | 1.74 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Data as of Jun 10 2024. Currency figures normalised to Ionis Pharmaceuticals Inc's reporting currency: US Dollar USD
58.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 21.86m | 15.00% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 13.32m | 9.14% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 13.22m | 9.07% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 8.30m | 5.69% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.53m | 5.17% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 5.70m | 3.91% |
| ClearBridge Investments LLCas of 31 Mar 2024 | 4.47m | 3.06% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.16m | 2.85% |
| Pictet Asset Management SAas of 31 Mar 2024 | 3.74m | 2.57% |
| Tweedy, Browne Co. LLCas of 31 Mar 2024 | 3.45m | 2.37% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
